Fat premium

25 November 2019 By Ed Cropley Follow @edwardcropley

The Swiss drugs giant is buying The Medicines Co. and its artery-clearing drug inclisiran for $9.7 bln, or a fat 41% premium. But the sector is crowded and Novartis must wait years for a decent return. Governments and insurers may also tire of paying to treat lifestyle diseases.

This content is for Subscribers only

Context News

Novartis said on Nov. 24 it had agreed to buy U.S. biotechnology firm The Medicines Company for $9.7 billion in cash.

The Swiss pharmaceutical company is paying $85 a share for The Medicines Company, whose top treatment is the cholesterol-lowering drug inclisiran.

Novartis said inclisiran, which has been shown in clinical trials to reduce cholesterol levels in the blood by up to 56%, would start to contribute to group sales in 2021.

Novartis shares were 0.3% higher at 90.03 Swiss francs at 0840 GMT on Nov. 25.

Email a friend

Please complete the form below.

Required fields *